VANDERBILT UNIVERSITY MEDICAL CENTER Findings from a recent study evaluating the impact of the antibiotic azithromycin during severe respiratory syncytial virus (RSV) bronchiolitis overwhelmingly support current national bronchiolitis guidelines, which recommend against antibiotics during acute bronchiolitis due to lack of effect on the acute illness. There is also substantial evidence that severe RSV bronchiolitis in...
Tag: <span>Azithromycin</span>
Post
Azithromycin trial fails to provide evidence of benefit in COVID-19
By Dr. Liji Thomas, MD, Dec 16 2020 Reviewed by Emily Henderson, B.Sc. Early on in the ongoing coronavirus disease 2019 (COVID-19) pandemic, the antibiotic azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hundreds of thousands of doses have been dispensed...
Post
The antibiotic paradox: why companies can’t afford to create life-saving drugs
Paratek Pharmaceuticals successfully brought a new antibiotic to the market. So why is the company’s long-term survival in question? A patient in South Africa battles a strain of tuberculosis that is resistant to multiple antibiotics. Drug resistance is a growing problem with many diseases. Credit: Joao Silva/NYT/Redux/eyevine PDF version As the COVID-19 pandemic caught hold...
Post
Addition of zinc may benefit some being treated for COVID-19
(HealthDay)—For hospitalized patients with COVID-19, the addition of zinc sulfate to hydroxychloroquine and azithromycin may improve some outcomes, according to a study not yet peer reviewed and posted on medRxiv.org. Philip M. Carlucci, from New York University Grossman School of Medicine in New York City, and colleagues collected data from electronic medical records for COVID-19...
Post
Hydroxychloroquine linked to increased risk of cardiac arrhythmias
Boston, Mass. — Since the World Health Organization declared COVID-19 a Public Health Concern of Global Interest on January 30, more than one million have tested positive for the illness in the United States, and more than 62,000 have died. With no FDA-approved treatments available to date, the anti-malarial drug, hydroxychloroquine, has emerged as a...
Post
More deaths, no benefit from malaria drug in VA virus study
With 368 patients, the study is the largest look so far of hydroxychloroquine with or without the antibiotic azithromycin for Covid-19. A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those...
Post
Chloroquine COVID-19 trial stopped after patient deaths
Researchers in Brazil were testing chloroquine in 81 hospitalized COVID-19 patients. About half were prescribed 450 mg twice daily for five days, and the others were prescribed 600 mg for 10 days, The New York Times reported. But within three days, some patients taking the higher dose developed serious heart rhythm disorders, resulting in 11...
Post
Azithromycin appears to reduce treatment failure in severe, acute COPD exacerbations
AMERICAN THORACIC SOCIETY May 3, 2019–The antibiotic azithromycin may reduce treatment failure in patients hospitalized for an acute exacerbation of chronic obstructive pulmonary disease(COPD), according to a randomized, controlled trial published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine. In “Azithromycin during Acute COPD Exacerbations Requiring Hospitalization (BACE): a Multicenter, Randomized, Double-blind, Placebo-controlled Trial,” researchers in...
Post
Azithromycin tied to poor airflow decline-free survival after HSCT
(HealthDay)—For patients after allogeneic hematopoietic stem cell transplant (HSCT), early administration of azithromycin is associated with worse airflow decline-free survival, according to a study published in the Aug. 8 issue of the Journal of the American Medical Association. Anne Bergeron, M.D., Ph.D., from the Hôpital Saint-Louis in Paris, and colleagues randomized patients to receive azithromycin or placebo three...